These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33858992)

  • 21. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
    Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
    Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Setmelanotide (Imcivree) for rare genetic forms of obesity.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism of the intracellular segments of the melanocortin-4 receptor for NDP-MSH signaling.
    Yang Y; Chen M; Loux TJ; Georgeson KE; Harmon CM
    Biochemistry; 2005 May; 44(18):6971-9. PubMed ID: 15865442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural insight into the MC4R conformational changes via different agonist-mediated receptor signaling.
    Yang Y; Chen M; Dimmitt R; Harmon CM
    Biochemistry; 2014 Nov; 53(45):7086-92. PubMed ID: 25347793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation.
    Fleck BA; Ling N; Chen C
    Biochemistry; 2007 Sep; 46(37):10473-83. PubMed ID: 17713970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options.
    Fani L; Bak S; Delhanty P; van Rossum EF; van den Akker EL
    Int J Obes (Lond); 2014 Feb; 38(2):163-9. PubMed ID: 23774329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.
    Xiang Z; Pogozheva ID; Sorenson NB; Wilczynski AM; Holder JR; Litherland SA; Millard WJ; Mosberg HI; Haskell-Luevano C
    Biochemistry; 2007 Jul; 46(28):8273-87. PubMed ID: 17590021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
    Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M
    Front Immunol; 2019; 10():2312. PubMed ID: 31636637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
    Kievit P; Halem H; Marks DL; Dong JZ; Glavas MM; Sinnayah P; Pranger L; Cowley MA; Grove KL; Culler MD
    Diabetes; 2013 Feb; 62(2):490-7. PubMed ID: 23048186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key amino acid residue in Melanocortin-1 receptor (melanocyte α-MSH receptor) for ligand selectivity.
    Yang Y; Chen M; Ventro G; Harmon CM
    Mol Cell Endocrinol; 2017 Oct; 454():69-76. PubMed ID: 28579117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal pathway analysis of selected obesity-associated melanocortin-4 receptor class V mutants.
    Sharma S; Thibodeau S; Lytton J
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165835. PubMed ID: 32423884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.
    Xiang Z; Proneth B; Dirain ML; Litherland SA; Haskell-Luevano C
    Biochemistry; 2010 Jun; 49(22):4583-600. PubMed ID: 20462274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the melanocortin-4 receptor structure identifies Ca
    Yu J; Gimenez LE; Hernandez CC; Wu Y; Wein AH; Han GW; McClary K; Mittal SR; Burdsall K; Stauch B; Wu L; Stevens SN; Peisley A; Williams SY; Chen V; Millhauser GL; Zhao S; Cone RD; Stevens RC
    Science; 2020 Apr; 368(6489):428-433. PubMed ID: 32327598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
    Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
    Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity.
    Rettenbacher E; Tarnow P; Brumm H; Prayer D; Wermter AK; Hebebrand J; Biebermann H; Hinney A; Widhalm K
    Exp Clin Endocrinol Diabetes; 2007 Jan; 115(1):7-12. PubMed ID: 17286227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential Signaling Profiles of MC4R Mutations with Three Different Ligands.
    Paisdzior S; Dimitriou IM; Schöpe PC; Annibale P; Scheerer P; Krude H; Lohse MJ; Biebermann H; Kühnen P
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
    Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA
    Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors.
    Mo XL; Tao YX
    Biochim Biophys Acta; 2013 Dec; 1832(12):1939-48. PubMed ID: 23791567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Setmelanotide optimization through fragment-growing, molecular docking in-silico method targeting MC4 receptor.
    Jia X; Fan S; Dong W; Li S; Zhang Y; Ma Y; Wang S
    J Biomol Struct Dyn; 2023; 41(24):15411-15420. PubMed ID: 37126536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.